CDR Tracker 2008 Annual Report

Content

 History of the Common Drug Review (CDR)

 Committees

 Submissions to Canada's Common Drug Review (CDR) CEDAC Recommendations

Overall: Yes vs. No

 Overall: Analysis of "Yes"

 Drug Categories: "Mainstream" and Biologics

 "Mainstream" Drugs: Yes vs. No

Biologic Drugs: Yes vs. No

Key CDR Timelines

NOC to CDR Submission

 CDR Submission to CEDAC Recommendation

Public Plan Reimbursement

Time to Listing - TTL

TTL: Notice of Compliance (NOC) to Listing

TTL: CEDAC Recommendation to Listing

CDR Tracker® Annual Report - Scorecard 2008

Common Drug Review Public Drug Plans

The Canadian Ranking Picture

Appendix 1: CDR Developments - 2008

 House of Commons Standing Committee on Health

 Brian O'Rourke - New Vice-President of CDR

 Pre-NOC Pilot Project

New Indication - Remicade® (infliximab)

CDR Consultations